 | |
| Clinical data | |
|---|---|
| Trade names | Xynor |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration |
Oral |
| ATC code | |
| Pharmacokinetic data | |
| Metabolism | Via liver |
| Elimination half-life | 12-13 hours |
| Excretion | Urine (63%) and Feces (22%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.037.099 |
| Chemical and physical data | |
| Formula | C7H10ClN3O3 |
| Molar mass | 219.63 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify)
| |
Ornidazole is an antibiotic used to treat protozoan infections. A synthetic nitroimidazole, it is commercially obtained from an acid-catalyzed reaction between 2-methyl-5-nitroimidazole and epichlorohydrin. Antimicrobial spectrum is similar to that of metronidazole and is more well tolerated; however there are concerns of lower relative efficacy.
It was first introduced for treating trichomoniasis before being recognized for its broad anti-protozoan and anti-anaerobic-bacterial capacities. has also been investigated for use in Crohn's disease after bowel resection.